Abstract 2057P
Background
Aging-related deficits that eventually manifest as frailty are emerging as an important determinant for quality of life and emotional health in older patients with cancer. Prevalence of frailty in long-term prostate cancer survivors and its impact on quality of life have not been investigated so far. The objective of the current study was (I) to assess the prevalence of frailty and (II) to elucidate the relationship between frailty, quality of life and emotional health in long-term prostate cancer survivors after radical prostatectomy.
Methods
2979 prostate cancer survivors from the multicenter German Familial Prostate Cancer Database were included. Patients completed the following standardized patient-reported outcome measures of interest: frailty (Groningen Frailty Indicator, GFI), quality of life (EORTC QL2), and emotional health (anxiety/depression symptoms, PHQ-4). Chi-square tests and Wilcoxon-Mann-Whitney tests were used to detect differences of selected variables between frail and non-frail patients. Associations were assessed using multiple linear regression analysis.
Results
The patients’ mean age was 79.4 years (SD = 6.4) and mean time since radical prostatectomy was 17.4 years (SD = 3.8). 33.1% (985/2979) of patients were classified as frail (GFI ≥4). Regarding mental health and quality of life, frail patients reported more often symptoms of depression (24.0% vs. 4.0%; p<0.001) and anxiety (20.6% vs. 2.0%; p<0.001) as well as lower quality of life (M = 53.4 (SD = 19.2) vs. M = 72.7 (SD = 16.0); p<0.001) compared to non-frail patients. Frailty was significantly associated with depression (OR 1.68; CI 1.49-1.89), anxiety (OR 1.75; CI 1.55-1.97), lower quality of life (OR 0.72; CI 0.67-0.77), higher age (OR 1.04; CI 1.03-1.07), and a missing partnership (OR 1.83; CI 1.37-2.45).
Conclusions
Every third long-term prostate cancer survivor after radical prostatectomy was frail. The associations with lower quality of life and poorer mental health indicates the need for an integrated care approach including further geriatric assessment and possible interventions to improve health outcomes of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06